Celgene Corporation (NASDAQ:CELG) – Investment analysts at Leerink Swann reduced their FY2017 EPS estimates for shares of Celgene Corporation in a research report issued to clients and investors on Monday. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will earn $6.78 per share for the year, down from their prior forecast of $6.79. Leerink Swann currently has a “Buy” rating and a $156.00 target price on the stock.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the business posted $1.58 earnings per share. Celgene Corporation’s quarterly revenue was up 10.2% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/fy2017-eps-estimates-for-celgene-corporation-cut-by-leerink-swann-celg.html.

Several other brokerages also recently commented on CELG. Morgan Stanley downgraded shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a report on Thursday, October 5th. Royal Bank Of Canada reiterated a “buy” rating and set a $173.00 price target on shares of Celgene Corporation in a report on Thursday, October 5th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price target on shares of Celgene Corporation in a report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price target on shares of Celgene Corporation in a report on Tuesday, September 26th. Finally, Bank of America Corporation reiterated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $139.64.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital Counsel LLC NY lifted its position in Celgene Corporation by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares during the last quarter. Fort Pitt Capital Group LLC lifted its position in Celgene Corporation by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 11 shares during the last quarter. Sowell Financial Services LLC lifted its position in Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 13 shares during the last quarter. South Texas Money Management Ltd. lifted its position in Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 15 shares during the last quarter. Finally, Flagship Harbor Advisors LLC lifted its position in Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 18 shares during the last quarter. 79.39% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now directly owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 38,733 shares of company stock valued at $5,259,359 in the last ninety days. Corporate insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Earnings History and Estimates for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.